SG Americas Securities
CYCN icon

SG Americas Securities’s Cyclerion Therapeutics CYCN Stock Holding History

SG Americas Securities’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-626
Closed -$74K – 2861
2020
Q2 		$74K Buy
+626
New +$52.3K ﹤0.01% 3458

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SG Americas Securities's CYCN Position: Q3 2020 in Review

SG Americas Securities sold out of Cyclerion Therapeutics (CYCN) in Q3 2020, closing a stake of 626 shares — an estimated $74K sold.

SG Americas Securities first reported a position in CYCN in Q2 2020 and held it in 1 quarter. The position peaked at $74K in Q2 2020. 73 funds tracked by Wall St. Rank hold CYCN as of Q3 2020.

  • SG Americas Securities reported no remaining Cyclerion Therapeutics position as of Q3 2020 after selling out during the quarter.
  • SG Americas Securities sold 626 Cyclerion Therapeutics shares in Q3 2020, an estimated $74K.
  • SG Americas Securities first reported a position in Cyclerion Therapeutics in Q2 2020 and held it in 1 quarter.
  • SG Americas Securities's Cyclerion Therapeutics position peaked at $74K in Q2 2020.
  • 73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2020.

Based on SG Americas Securities's 13F filing for Q3 2020, filed 9 Nov 2020.